Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the tr… Read more
Eterna Therapeutics Inc (ERNA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.356x
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has a cash flow conversion efficiency ratio of -0.356x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.27 Million) by net assets ($3.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eterna Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Eterna Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eterna Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eterna Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Engine Group Holding Limited Ordinary Shares
NASDAQ:GLE
|
-0.028x |
|
Alkali Metals Limited
NSE:ALKALI
|
0.042x |
|
Zephyr Minerals Ltd
PINK:ZPHYF
|
0.006x |
|
Suryamas Dutamakmur Tbk
JK:SMDM
|
-0.014x |
|
Planigrupo LATAM S.A.B. de C.V
MX:PLANI
|
0.043x |
|
Falcon Gold Corp
OTCQB:FGLDF
|
-0.004x |
|
Jayud Global Logistics Limited Class A Ordinary Shares
NASDAQ:JYD
|
-0.145x |
|
Radana Bhaskara Finance Tbk
JK:HDFA
|
-0.240x |
Annual Cash Flow Conversion Efficiency for Eterna Therapeutics Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of Eterna Therapeutics Inc from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.70 Million | $-15.84 Million | -9.310x | -1.87% |
| 2023-12-31 | $2.23 Million | $-20.41 Million | -9.139x | -427.50% |
| 2022-12-31 | $12.11 Million | $-20.98 Million | -1.733x | -88.13% |
| 2021-12-31 | $25.50 Million | $-23.49 Million | -0.921x | +12.93% |
| 2020-12-31 | $7.66 Million | $-8.10 Million | -1.058x | -296.24% |
| 2019-12-31 | $5.09 Million | $2.74 Million | 0.539x | +173.13% |
| 2018-12-31 | $6.92 Million | $1.36 Million | 0.197x | +98.99% |
| 2017-12-31 | $5.54 Million | $549.00K | 0.099x | +1654.00% |
| 2016-12-31 | $4.07 Million | $23.00K | 0.006x | +100.52% |
| 2015-12-31 | $3.85 Million | $-4.18 Million | -1.086x | -85.85% |
| 2014-12-31 | $10.92 Million | $-6.38 Million | -0.584x | -460.25% |
| 2013-12-31 | $9.20 Million | $1.49 Million | 0.162x | -40.59% |
| 2012-12-31 | $7.89 Million | $2.16 Million | 0.273x | +202.14% |
| 2011-12-31 | $6.35 Million | $574.00K | 0.090x | -69.79% |
| 2010-12-31 | $9.46 Million | $2.83 Million | 0.299x | +12.59% |
| 2009-12-31 | $9.42 Million | $2.50 Million | 0.266x | +100.69% |
| 2007-12-31 | $15.57 Million | $-604.00 Million | -38.798x | -- |